Clinical Trials Logo

Clinical Trial Summary

To understand efficacy of Durvalumab(MEDI4736)+ Tremelimumab in Metastatic/relapsed pulmonary sarcomatoid carcinoma


Clinical Trial Description

This is a phase II multi-center, open-label study to evaluate efficacy and safety of durvalumab + tremelimumab combination treatment in patients with pulmonary sarcomatoid carcinoma ;


Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC

NCT number NCT03022500
Study type Interventional
Source Seoul National University Hospital
Contact
Status Completed
Phase Phase 2
Start date May 18, 2017
Completion date November 30, 2019